Silence Therapeutics (SLN) Other Working Capital Changes (2024 - 2026)

Silence Therapeutics has disclosed Other Working Capital Changes across 3 years of filings, most recently posting -$24000.0 for Q1 2026.

• Other Working Capital Changes for Q1 2026 came in at -$24000.0, down 104.05% year-over-year; the trailing twelve-month figure through Mar 2026 was -$784000.0 (up 97.29% YoY), and the FY2025 annual result was $110379.0, down 75.9% from the prior year.
• Other Working Capital Changes came in at -$24000.0 for Q1 2026 at Silence Therapeutics, down from -$22000.0 in the prior quarter.
• In the past five years, Other Working Capital Changes ranged from a high of $5.7 million in Q3 2024 to a low of -$30.5 million in Q4 2024.
• The 3-year median for Other Working Capital Changes is -$22000.0 (2025), against an average of -$3.2 million.
• Across the five-year window, Other Working Capital Changes surged 99.93% in 2025 and sank 104.05% in 2026, its largest moves.
• Silence Therapeutics' Other Working Capital Changes stood at -$30.5 million in 2024, then soared by 99.93% to -$22000.0 in 2025, then decreased by 9.09% to -$24000.0 in 2026.
• The last three Other Working Capital Changes figures came in at -$24000.0 (Q1 2026), -$22000.0 (Q4 2025), and $2.3 million (Q3 2025), per Business Quant data.